Sirio Pharma
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; probiotic balls; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. … Read more
Sirio Pharma (300791) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: 0.035x
Based on the latest financial reports, Sirio Pharma (300791) has a cash flow conversion efficiency ratio of 0.035x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥101.61 Million) by net assets (CN¥2.91 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sirio Pharma - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sirio Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sirio Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sirio Pharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Yuanlong Yato Culture Dissemination Co Ltd
SHE:002878
|
-0.092x |
|
Beijing Century Real Tech
SHE:300150
|
0.050x |
|
First Bank
NASDAQ:FRBA
|
0.039x |
|
PERSONALIS INC. DL-001
F:04X
|
N/A |
|
Luxfer Holdings PLC
NYSE:LXFR
|
0.052x |
|
Yuanta Futures Co Ltd
TWO:6023
|
0.103x |
|
Suzhou Kelida Bldg &
SHG:603828
|
0.085x |
|
Anhui Ankai Automobile Co Ltd
SHE:000868
|
0.002x |
Annual Cash Flow Conversion Efficiency for Sirio Pharma (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sirio Pharma from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.64 Billion | CN¥566.97 Million | 0.215x | +42.68% |
| 2023-12-31 | CN¥2.57 Billion | CN¥386.08 Million | 0.150x | -8.63% |
| 2022-12-31 | CN¥2.70 Billion | CN¥444.86 Million | 0.165x | +22.75% |
| 2021-12-31 | CN¥2.54 Billion | CN¥341.38 Million | 0.134x | -8.38% |
| 2020-12-31 | CN¥2.18 Billion | CN¥319.57 Million | 0.146x | +22.96% |
| 2019-12-31 | CN¥1.95 Billion | CN¥231.60 Million | 0.119x | -49.11% |
| 2018-12-31 | CN¥784.05 Million | CN¥183.46 Million | 0.234x | +175.08% |
| 2017-12-31 | CN¥580.20 Million | CN¥49.35 Million | 0.085x | +140.25% |
| 2016-12-31 | CN¥464.98 Million | CN¥-98.26 Million | -0.211x | -- |